Table 2.
Associated Proteins or Signaling Pathways | Role of NGLY1 | References |
---|---|---|
ERAD pathway | Deglycosylation of misfolded proteins | Hirsch et al., 2003 [67] Grotzke et al., 2013 [71] Hosomi & Suzuki, 2015 [68] Hosomi et al., 2016 [74] |
BMP signaling (BMP4/Dpp) | Deglycosylation and retrotranslocation of misfolded BMP4/Dpp | Galeone et al., 2017 [55] Galeone et al., 2020 [40] |
AMP kinase signaling and mitochondrial structural integrity | Regulation of AMPKα mRNA level | Han et al., 2020 [99] |
Proteasomal homeostasis | Regulation of proteasomal bounce-back response by deglycosylation and activation of NFE2L1 | Lehrbach et. al., 2016 [60] Tomlin et al., 2018 [94] |
Resistance to hypotonic cell lysis | Non-enzymatic transcriptional regulation of aquaporin expression, in part through ATF1/CREB1 | Tambe et al., 2019 [154] |
Na+, K+, 2Cl– ion transport | Regulation of NKCC1 function, potentially through NKCC1 deglycosylation | Talsness et al., 2020 [152] |
Mitophagy and mitochondrial homeostasis | Regulation of mitochondrial biogenesis and mitophagy-related gene expression by deglycosylation and activation of NFE2L1 | Yang et al., 2018 [44] |
Innate immune signaling | Suppression of interferon signaling, at least in part through the DNA-sensing cGAS-STING pathway | Yang et al., 2018 [44] Zolekar et al., 2018 [110] |
Melanoma survival and growth | Suppression of stress-signaling-associated apoptosis and cytokine surge | Zolekar et al., 2018 [110] |
Ferroptosis | Resistance to ferroptosis through NFE2L1 deglycosylation | Forcina et al., 2022 [100] |